Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: A single center experience

Abstract

Background: In 2006 the Hematology Service of Hospital Maciel published its experience with peripheral blood progenitor cell harvesting for autologous stem cell transplantation using Filgen JP (Clausen Filgrastim). After mobilization with a mean filgrastim dose of 78 mcg/Kg, 4.7 × 10 6 CD34 + cells/Kg were obtained by apheresis. Age above 50, multiple myeloma as underlying disease and a malignancy that was not in remission were identified as frequent characteristics among patients showing complex mobilization. Objective: The aim of this study was to compare stem cell mobilization using different brands of filgrastim. Methods: One hundred and fifty-seven mobilizations performed between 1997 and 2006 were analyzed. This retrospective analysis comparative two groups of patients: those mobilized with different brands of filgrastim (Group A) and those who received Filgen JP (Clausen Filgrastim) as mobilizing agent (Group B). A cluster analysis technique was used to identify four clusters of individuals with different behaviors differentiated by age, total dose of filgrastim required, number of apheresis and harvested CD34 + cells. Results: The mean total dose of filgrastim administered was 105 mcg/Kg, the median number of apheresis was 2 procedures and the mean number of harvested stem cells was 4.98 × 10 6 CD34 + cells/Kg. No significant differences were observed between Groups A and B regarding the number of apheresis, harvested CD34 + cells and number of mobilization failures, however the total dose of filgrastim was significantly lower in Group B. Conclusions: Among other factors, the origin of the cytokine used as mobilizing agent is an element to be considered when evaluating CD34 + cell mobilization results.